Dr. Jay Mei is the founder, chairman and CEO of Antengene. Prior to founding the company, Dr. Mei has more than twenty years of cancer research and drug development experience, and worked at the US National Cancer Institute (NCI) as well as several multi-national pharmaceutical companies, including Johnson & Johnson Pharmaceutical R&D (J&JPRD), Novartis Oncology and Celgene Corporation. As an Executive Director of Clinical Development at Celgene Corporation, Dr. Mei successfully led the development of REVLIMID® (lenalidomide) in China. REVLIMID® received CFDA approval and was launched in China in 2013. Outside the China market, Dr. Mei was responsible for the clinical trials of REVLIMID® in more than 30 countries. He was also the clinical lead at Celgene on IDHIFA® (enasidenib) which received the FDA approval for relapsed or refractory AML.
Before joining Celgene in 2008, Dr. Mei served in multiple clinical development roles at J&JPRD and Novartis Oncology. Prior to industry, Dr. Mei spent eight years on cancer and clinical research at the NCI. Over more than twenty years of his career in academia and industry, Dr. Mei has been an author on over 70 publications and holds multiple patents.
Dr. Mei graduated from the English Medicine Class, an exchange program sponsored by the Yale China Foundation, at Xiang-Ya Medical College. He subsequently received his Ph.D. in Pharmacology/Toxicology from the University of Maryland in Baltimore. Dr. Mei lectured at the University of Pennsylvania School of Medicine on clinical research and is an adjunct professor at Xiang-Ya Medical College in China.
Dr. Hans de Haan graduated in medicine from King’s College, London University, England and held various clinical and teaching positions at London University and at the British Medical Research Council before joining the pharmaceutical industry. During the past 40 years he has held positions in companies (Zeneca, Warner-Lambert and Boots Pharmaceuticals) researching most aspects of international pharmaceutical drug development, involving basic (laboratory) research, all phases of clinical research, licensing and marketing and been a consultant to pharmaceutical and biotechnology companies in the USA and world-wide. In addition to a medical degree, Dr. de Haan has higher qualifications in surgery, pharmaceutical medicine and a doctoral degree in organizational psychology, specializing in biotechnology. He has been adjunct faculty teaching and examining in the fields of pharmacology and psychology and is a past President of the American Academy of Pharmaceutical Physicians.
Dr. Lee Kang holds PhD in Chemistry from Virginia Tech and MBA from the State University of New York (SUNY) at Buffalo. He has a combined 25 years of industrial experiences at Bristol-Myers Squibb, Pfizer, Sanofi, and Perrigo Companies in various capacities of pharmaceutical manufacturing, regulatory affairs, quality assurance, and supply chain management. Dr. Kang has guided the chemistry manufacturing and controls (CMC) groups to support global clinical trials, with over 100 submissions of IND, IMPD, dealt with regulatory inquiries, and directly contributed to NDA and market launches for both brand-name drugs, such as Effexor® (venlafaxine), Enbrel® (etanercept), Plavix® (clopidogrel), Ambien® (zolpidem), and several generic drugs. He has held managerial positions with high exposure to regulatory agencies for activities such as tech transfer and preapproval inspections (PAI) by US FDA and UK MHRA. Dr. Kang has also directly overseen supply chain operations for sourcing medicinal products from China, India, and other Pacific Rim regions/countries. In recent years, Dr. Kang has provided consultancy to Chinese companies regarding GMP quality, risk management, M&A, and marketing. Dr. Kang has been an adjunct visiting professor in School of Pharmacy, SUNY at Buffalo. Dr. Kang is a Certified Quality Auditor (CQA) by American Society of Quality (ASQ). Dr. Kang presents and publishes frequently and holds patents in medical devices.
Dr. Robert A. Galemmo is a PhD medicinal chemist with over 30 years of experience in the pharmaceutical industry. His drug discovery teams have delivered development and clinical candidates in multiple therapeutic areas including gastrointestinal, allergy and anti-inflammatory, cardiovascular, oncology, pain and neurodegeneration.
When he was a bench scientist at Rhone-Poulenc Rorer, he designed and synthesized the clinical leukotriene antagonist RG 12525, which was evaluated in the clinic as an anti-inflammatory agent for asthma. As chemistry leader of the oncology team at Johnson & Johnson in Spring House PA, his group discovered the highly selective MET kinase inhibitor JNJ 38877605, currently under clinical evaluation in the EU. While at DuPont Pharmaceuticals, Dr. Galemmo initiated the factor Xa inhibitor program and led the early effort that resulted in the oral anti-coagulant Eliquis® (apixaban). This drug is currently marketed by Bristol Meyers Squibb and Pfizer with sales reaching $1.2 billion in 2017.
Bob is a co-Founder and President of ProteXase Therapeutics, a pre-clinical stage start-up company pioneering a new approach to overcoming therapeutic resistance in targeted chemotherapy. He serves as an Advisor to the California Life Sciences Institute and several biotechnology start-up companies in the San Francisco Bay Area. He has published over 50 scientific peer-reviewed papers and is a co-inventor on over 40 granted US patents.
Dr. Yang holds Ph.D. in Biostatistics from Boston University and Sc.D. in Clinical Epidemiology from the Netherlands Institute for Health Sciences. During the past 20 years, Dr. Yang held positions at Harvard and in multiple Pharmaceuticals and biotechnology companies, including Bristol Myers Squibb China, Wyeth, Vertex Pharmaceuticals, Acceleron Pharmaceuticals, MediVector Inc, Synageva BioPharma (Alexion), Forum Pharmaceuticals and Ziopharm Oncology in the function of biostatistics and clinical pharmacology to support clinical development programs and regulatory submissions. His responsibilities at these companies include study design for all phases of clinical trials, with statistical and clinical pharmacology input, statistical method selection, data management, clinical trial data analysis and interpretation, PK/PD analysis, manuscript publications, and regulatory submission for NDA/BLA/MAA. He participated in the clinical development approvals of multiple therapeutics, including Incivek® (telaprevir), Torisel® (temsirolimus) and Kanuma® (sebelipase alfa). With his guidance, these companies have successfully built biostatistics teams which optimize clinical trial program and improve efficiency.
Dr. Shan has over 15 years pharmaceutical experience in R&D and manufacturing in Europe and China. Most recently, he was Vice President at Ascletis Pharmaceuticals Ltd., lead interdisciplinary teams to deliver a number of IND and NDA programs, delivered one NDA filing and one IND filing at clinical phase III stage. As the site head for production plant, Dr. Shan was responsible for the construction and validation of the whole production facility which passed the CFDA GMP inspection in 2018. Prior to his position at Ascletis, Dr. Shan held several senior positions for companies, including Chempartner, Gateway Pharmaceutical Ltd and GE Healthcare. Dr. Shan holds a Ph.D. in Medicinal Chemistry from Aston University in the UK and an honorary research position at Imperial College London.